

Maria Orietta Borghi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1901138/publications.pdf>

Version: 2024-02-01

130
papers

5,646
citations

66234

42
h-index

88477

70
g-index

134
all docs

134
docs citations

134
times ranked

5468
citing authors

#	ARTICLE	IF	CITATIONS
1	Production of anti-PF4 antibodies in antiphospholipid antibody-positive patients is not affected by COVID-19 vaccination. <i>RMD Open</i> , 2022, 8, e001902.	1.8	7
2	Role of Epigenetic Therapy in the Modulation of Tumor Growth and Migration in Human Castration-Resistant Prostate Cancer Cells with Neuroendocrine Differentiation. <i>Neuroendocrinology</i> , 2022, 112, 580-594.	1.2	2
3	Antibodies and diagnostic tests in antiphospholipid syndrome. , 2021, , 565-574.		1
4	Integrative Analysis Reveals a Molecular Stratification of Systemic Autoimmune Diseases. <i>Arthritis and Rheumatology</i> , 2021, 73, 1073-1085.	2.9	81
5	Complement activation and endothelial perturbation parallel COVID-19 severity and activity. <i>Journal of Autoimmunity</i> , 2021, 116, 102560.	3.0	127
6	Cerebrospinal fluid phosphorylated neurofilament heavy chain and chitotriosidase in primary lateral sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021, 92, 221-223.	0.9	9
7	Î22 glycoprotein I participates in phagocytosis of apoptotic neurons and in vascular injury in experimental brain stroke. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2021, 41, 0271678X2098455.	2.4	8
8	Vandetanib versus Cabozantinib in Medullary Thyroid Carcinoma: A Focus on Anti-Angiogenic Effects in Zebrafish Model. <i>International Journal of Molecular Sciences</i> , 2021, 22, 3031.	1.8	9
9	Histone Deacetylase Inhibitors Ameliorate Morphological Defects and Hypoexcitability of iPSC-Neurons from Rubinstein-Taybi Patients. <i>International Journal of Molecular Sciences</i> , 2021, 22, 5777.	1.8	7
10	Antiphospholipid antibodies and COVID-19 thrombotic vasculopathy: one swallow does not make a summer. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1105-1107.	0.5	12
11	Antiphospholipid Antibody Assays in 2021: Looking for a Predictive Value in Addition to a Diagnostic One. <i>Frontiers in Immunology</i> , 2021, 12, 726820.	2.2	21
12	EUREKA algorithm predicts obstetric risk and response to treatment in women with different subsets of anti-phospholipid antibodies. <i>Rheumatology</i> , 2021, 60, 1114-1124.	0.9	41
13	Two Novel Technologies for the Detection of Anti-cardiolipin and Anti Î22â€“Glycoprotein Antibodies in the Real Life: Chemiluminescent in Comparison to the Addressable Laser Bead Immunoassays. <i>Immunological Investigations</i> , 2020, 49, 58-68.	1.0	4
14	Complement Activation and Thrombin Generation by MBL Bound to Î22-Glycoprotein I. <i>Journal of Immunology</i> , 2020, 205, 1385-1392.	0.4	16
15	Efficacy of a novel second-generation somatostatin-dopamine chimera (TBR-065) in human medullary thyroid cancer: a preclinical study. <i>Neuroendocrinology</i> , 2020, 111, 937-950.	1.2	4
16	Anti-Phospholipid Antibodies in COVID-19 Are Different From Those Detectable in the Anti-Phospholipid Syndrome. <i>Frontiers in Immunology</i> , 2020, 11, 584241.	2.2	137
17	O31â€“...Integrative analysis reveals a molecular stratification of systemic autoimmune diseases. , 2020, , .		1
18	Understanding and interpreting antinuclear antibody tests in systemic rheumatic diseases. <i>Nature Reviews Rheumatology</i> , 2020, 16, 715-726.	3.5	85

#	ARTICLE	IF	CITATIONS
19	Scleroderma-specific autoantibodies embedded in immune complexes mediate endothelial damage: an early event in the pathogenesis of systemic sclerosis. <i>Arthritis Research and Therapy</i> , 2020, 22, 265.	1.6	33
20	Personalized medicine in rheumatoid arthritis: How immunogenicity impacts use of TNF inhibitors. <i>Autoimmunity Reviews</i> , 2020, 19, 102509.	2.5	13
21	In utero exposure to Azathioprine in autoimmune disease. <i>Where do we stand?.</i> <i>Autoimmunity Reviews</i> , 2020, 19, 102525.	2.5	22
22	Only monospecific anti-DFS70 antibodies aid in the exclusion of antinuclear antibody associated rheumatic diseases: an Italian experience. <i>Clinical Chemistry and Laboratory Medicine</i> , 2019, 57, 1764-1769.	1.4	25
23	Blood Cell-Bound C4d as a Marker of Complement Activation in Patients With the Antiphospholipid Syndrome. <i>Frontiers in Immunology</i> , 2019, 10, 773.	2.2	28
24	Interleukin-17/Interleukin-21 and Interferon- γ producing T cells specific for β_2 Glycoprotein I in atherosclerosis inflammation of systemic lupus erythematosus patients with antiphospholipid syndrome. <i>Haematologica</i> , 2019, 104, 2519-2527.	1.7	19
25	FRIO186...HYDROXYCHLOROQUINE ON THE TOP OF STANDARD TREATMENT WITH LOW DOSE ASPIRIN AND LOW MOLECULAR WEIGHT HEPARIN SIGNIFICANTLY REDUCES THE PROBABILITY OF PREGNANCY MORBIDITY IN WOMEN WITH MULTIPLE POSITIVITY FOR ANTI-PHOSPHOLIPID ANTIBODIES. , 2019, , .		0
26	ABO201...THE PATHOGENIC EFFECTS OF IMMUNE COMPLEXES CONTAINING SCLERODERMA-SPECIFIC AUTOANTIBODIES IN ENDOTHELIAL CELLS. , 2019, , .		0
27	FRIO185...HYDROXYCHLOROQUINE FOR THE PREVENTION OF RELAPSES IN A SERIES OF 812 PATIENTS WITH PRIMARY ANTIPHOSPHOLIPID SYNDROME: THE HIBISCUS RETROSPECTIVE STUDY. , 2019, , .		0
28	New insight into antiphospholipid syndrome: antibodies to β_2 glycoprotein I-domain 5 fail to induce thrombi in rats. <i>Haematologica</i> , 2019, 104, 819-826.	1.7	40
29	Detection of anti-adalimumab antibodies in a RA responsive cohort of patients using three different techniques. <i>Analytical Biochemistry</i> , 2019, 566, 133-138.	1.1	7
30	Pitfalls of antinuclear antibody detection in systemic lupus erythematosus: the positive experience of a national multicentre study. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, e50-e50.	0.5	16
31	Beyond thrombosis: Anti- β_2 GPI domain 1 antibodies identify late pregnancy morbidity in anti-phospholipid syndrome. <i>Journal of Autoimmunity</i> , 2018, 90, 76-83.	3.0	60
32	Diagnostic laboratory tests for systemic autoimmune rheumatic diseases: unmet needs towards harmonization. <i>Clinical Chemistry and Laboratory Medicine</i> , 2018, 56, 1743-1748.	1.4	22
33	Effects of human recombinant type I IFNs (IFN- β and IFN- α) on growth and migration of primary endometrial stromal cells from women with deeply infiltrating endometriosis: A preliminary study. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2018, 230, 192-198.	0.5	7
34	HIBISCUS: Hydroxychloroquine for the secondary prevention of thrombotic and obstetrical events in primary antiphospholipid syndrome. <i>Autoimmunity Reviews</i> , 2018, 17, 1153-1168.	2.5	62
35	Immune complexes containing scleroderma-specific autoantibodies induce a profibrotic and proinflammatory phenotype in skin fibroblasts. <i>Arthritis Research and Therapy</i> , 2018, 20, 187.	1.6	33
36	Pathogenic Role of Complement in Antiphospholipid Syndrome and Therapeutic Implications. <i>Frontiers in Immunology</i> , 2018, 9, 1388.	2.2	51

#	ARTICLE	IF	CITATIONS
37	Obstetric and vascular antiphospholipid syndrome: same antibodies but different diseases?. <i>Nature Reviews Rheumatology</i> , 2018, 14, 433-440.	3.5	95
38	Vitamin D and Anti-Phospholipid Antibody Syndrome: A Comprehensive Review. <i>Open Rheumatology Journal</i> , 2018, 12, 248-260.	0.1	5
39	Mechanisms of Action of the Antiphospholipid Antibodies. <i>Handbook of Systemic Autoimmune Diseases</i> , 2017, 12, 31-46.	0.1	1
40	Î22 Glycoprotein I Recognition Drives Th1 Inflammation in Atherosclerotic Plaques of Patients with Primary Antiphospholipid Syndrome. <i>Journal of Immunology</i> , 2017, 198, 2640-2648.	0.4	34
41	Antitumor activity of interferon-Î21a in hormone refractory prostate cancer with neuroendocrine differentiation. <i>Journal of Endocrinological Investigation</i> , 2017, 40, 761-770.	1.8	10
42	Synergistic activity of everolimus and 5-azadeoxycytidine in medullary thyroid carcinoma cell lines. <i>Molecular Oncology</i> , 2017, 11, 1007-1022.	2.1	23
43	Detection of early endothelial damage in patients with Raynaud's phenomenon. <i>Microvascular Research</i> , 2017, 113, 22-28.	1.1	19
44	8-Cl-cAMP and PKA I-selective cAMP analogs effectively inhibit undifferentiated thyroid cancer cell growth. <i>Endocrine</i> , 2017, 56, 388-398.	1.1	2
45	Oxidation of Î22-glycoprotein I associates with IgG antibodies to domain I in patients with antiphospholipid syndrome. <i>PLoS ONE</i> , 2017, 12, e0186513.	1.1	8
46	Clinical and Prognostic Significance of Non-criteria Antiphospholipid Antibody Tests. , 2017, , 171-187.		3
47	Complement activation in antiphospholipid syndrome and its inhibition to prevent rethrombosis after arterial surgery. <i>Blood</i> , 2016, 127, 365-367.	0.6	67
48	Antiphospholipid antibodies detected by line immunoassay differentiate among patients with antiphospholipid syndrome, with infections and asymptomatic carriers. <i>Arthritis Research and Therapy</i> , 2016, 18, 111.	1.6	32
49	Gene-specific mitochondria dysfunctions in human TARDBP and C9ORF72 fibroblasts. <i>Acta Neuropathologica Communications</i> , 2016, 4, 47.	2.4	147
50	The challenges of lupus anticoagulants. <i>Expert Review of Hematology</i> , 2016, 9, 389-400.	1.0	31
51	The cAMP analogs have potent anti-proliferative effects on medullary thyroid cancer cell lines. <i>Endocrine</i> , 2016, 51, 101-112.	1.1	16
52	Antibodies and Diagnostic Tests in Antiphospholipid Syndrome. , 2016, , 495-501.		0
53	Update on the pathogenesis and treatment of the antiphospholipid syndrome. <i>Current Opinion in Rheumatology</i> , 2015, 27, 476-482.	2.0	35
54	Newly Identified Antiatherosclerotic Activity of Methotrexate and Adalimumab: Complementary Effects on Lipoprotein Function and Macrophage Cholesterol Metabolism. <i>Arthritis and Rheumatology</i> , 2015, 67, 1155-1164.	2.9	94

#	ARTICLE	IF	CITATIONS
55	Clinical Characterization of Antiphospholipid Syndrome by Detection of IgG Antibodies Against β_2 -Glycoprotein I Domain 1 and Domain 4/5: Ratio of Anti-“Domain 1 to Anti-“Domain 4/5 As a Useful New Biomarker for Antiphospholipid Syndrome. <i>Arthritis and Rheumatology</i> , 2015, 67, 2196-2204.	2.9	94
56	Simultaneous Automated Screening and Confirmatory Testing for Vasculitis-Specific ANCA. <i>PLoS ONE</i> , 2014, 9, e107743.	1.1	33
57	Toll-like receptor 4 and β_2 glycoprotein I interaction on endothelial cells. <i>Lupus</i> , 2014, 23, 1302-1304.	0.8	23
58	International standards for IgG and IgM anti- β_2 glycoprotein antibody measurement. <i>Lupus</i> , 2014, 23, 1317-1319.	0.8	13
59	Antiendothelial Cell Antibodies. , 2014, , 723-729.		0
60	Impaired serum cholesterol efflux capacity in rheumatoid arthritis and systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 609-615.	0.5	132
61	Automated tests of ANA immunofluorescence as throughput autoantibody detection technology: strengths and limitations. <i>BMC Medicine</i> , 2014, 12, 38.	2.3	53
62	Autoantibody profiling in APS. <i>Lupus</i> , 2014, 23, 1262-1264.	0.8	13
63	Standardization of autoantibody testing: a paradigm for serology in rheumatic diseases. <i>Nature Reviews Rheumatology</i> , 2014, 10, 35-43.	3.5	70
64	Immune parameters identify Italian centenarians with a longer five-year survival independent of their health and functional status. <i>Experimental Gerontology</i> , 2014, 54, 14-20.	1.2	34
65	β_2 -glycoprotein I, lipopolysaccharide and endothelial TLR4: Three players in the two hit theory for anti-phospholipid-mediated thrombosis. <i>Journal of Autoimmunity</i> , 2014, 55, 42-50.	3.0	52
66	A non-“complement-fixing antibody to β_2 glycoprotein I as a novel therapy for antiphospholipid syndrome. <i>Blood</i> , 2014, 123, 3478-3487.	0.6	120
67	Anti-phosphatidylserine/prothrombin antibodies: an additional diagnostic marker for APS?. <i>Immunologic Research</i> , 2013, 56, 432-438.	1.3	57
68	A5.5-“Antibodies against Domain I of β_2 Glycoprotein I in Antiphospholipid Antibody Syndrome. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, A31.3-A32.	0.5	0
69	What is the Genetics of Antiphospholipid Antibodies/Syndrome?. , 2012, , 41-56.		0
70	Preliminary evaluation of the first international reference preparation for anticitrullinated peptide antibodies. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1388-1392.	0.5	17
71	Obstetric and vascular APS: Same autoantibodies but different diseases?. <i>Lupus</i> , 2012, 21, 708-710.	0.8	41
72	Anti-phospholipid induced murine fetal loss: Novel protective effect of a peptide targeting the β_2 glycoprotein I phospholipid-binding site. Implications for human fetal loss. <i>Journal of Autoimmunity</i> , 2012, 38, J209-J215.	3.0	58

#	ARTICLE	IF	CITATIONS
73	Everolimus is an active agent in medullary thyroid cancer: a clinical and <i>in vitro</i> study. <i>Journal of Cellular and Molecular Medicine</i> , 2012, 16, 1563-1572.	1.6	42
74	Interferon-inducible genes, TNF-related apoptosis-inducing ligand (TRAIL) and interferon inducible protein 27 (IFI27) are negatively regulated in leiomyomas: implications for a role of the interferon pathway in leiomyoma development. <i>Gynecological Endocrinology</i> , 2012, 28, 216-219.	0.7	9
75	Automated interpretation of ANCA patterns - a new approach in the serology of ANCA-associated vasculitis. <i>Arthritis Research and Therapy</i> , 2012, 14, R271.	1.6	39
76	What is the Mechanism(s) of Antiphospholipid Antibody-Mediated Pregnancy Morbidity?. , 2012, , 79-101.		1
77	Pathogenesis of antiphospholipid syndrome: understanding the antibodies. <i>Nature Reviews Rheumatology</i> , 2011, 7, 330-339.	3.5	482
78	In vivo distribution of β_2 glycoprotein I under various pathophysiologic conditions. <i>Blood</i> , 2011, 118, 4231-4238.	0.6	113
79	8-Chloro-Cyclic AMP and Protein Kinase A I-Selective Cyclic AMP Analogs Inhibit Cancer Cell Growth through Different Mechanisms. <i>PLoS ONE</i> , 2011, 6, e20785.	1.1	26
80	IRF5 is associated with primary antiphospholipid syndrome, but is not a major risk factor. <i>Arthritis and Rheumatism</i> , 2010, 62, 1201-1202.	6.7	17
81	Decreased expression of heparin-binding epidermal growth factor-like growth factor as a newly identified pathogenic mechanism of antiphospholipid-mediated defective placentation. <i>Arthritis and Rheumatism</i> , 2010, 62, 1504-1512.	6.7	51
82	Anti-phospholipid antibody mediated fetal loss: still an open question from a pathogenic point of view. <i>Lupus</i> , 2010, 19, 453-456.	0.8	53
83	Patients with antiphospholipid syndrome display endothelial perturbation. <i>Journal of Autoimmunity</i> , 2010, 34, 105-110.	3.0	82
84	Anti- β_2 -glycoprotein I ELISA assay: The influence of different antigen preparations. <i>Thrombosis and Haemostasis</i> , 2009, 101, 789-791.	1.8	11
85	European Forum on Antiphospholipid Antibodies: research in progress. <i>Lupus</i> , 2009, 18, 924-929.	0.8	5
86	Association of <i>STAT4</i> and <i>BLK</i> , but not <i>BANK1</i> or <i>IRF5</i> , with primary antiphospholipid syndrome. <i>Arthritis and Rheumatism</i> , 2009, 60, 2468-2471.	6.7	66
87	Pro-inflammatory genotype as a risk factor for aPL-associated thrombosis: Report of a family with multiple anti-phospholipid positive members. <i>Journal of Autoimmunity</i> , 2009, 32, 60-63.	3.0	28
88	Chapter 4 Mechanisms of Action of Antiphospholipid Antibodies. <i>Handbook of Systemic Autoimmune Diseases</i> , 2009, 10, 55-67.	0.1	4
89	Updating on the Pathogenic Mechanisms 5 of the Antiphospholipid Antibodies-Associated Pregnancy Loss. <i>Clinical Reviews in Allergy and Immunology</i> , 2008, 34, 332-337.	2.9	38
90	Toll-like receptors: another player in the pathogenesis of the anti-phospholipid syndrome. <i>Lupus</i> , 2008, 17, 938-943.	0.8	63

#	ARTICLE	IF	CITATIONS
91	Antiphospholipid Antibodies and the Antiphospholipid Syndrome: Pathogenic Mechanisms. <i>Seminars in Thrombosis and Hemostasis</i> , 2008, 34, 236-250.	1.5	205
92	Toll-like receptor and antiphospholipid mediated thrombosis: in vivo studies. <i>Annals of the Rheumatic Diseases</i> , 2007, 66, 1327-1333.	0.5	184
93	Immune function in children born to mothers with autoimmune diseases and exposed in utero to immunosuppressants. <i>Lupus</i> , 2007, 16, 651-656.	0.8	34
94	ANTI-ENDOTHELIAL CELL AUTOANTIBODIES. , 2007, , 725-731.		4
95	Role of anti-Î²2 glycoprotein I antibodies in antiphospholipid syndrome. <i>Clinical Reviews in Allergy and Immunology</i> , 2007, 32, 67-73.	2.9	23
96	Anti-Beta-2 Glycoprotein I Antibodies Affect Bcl-2 and Bax Trophoblast Expression without Evidence of Apoptosis. <i>Annals of the New York Academy of Sciences</i> , 2006, 1069, 364-376.	1.8	28
97	Transforming growth factor Î²1 in the pathogenesis of autoimmune congenital complete heart block: Lesson from twins and triplets discordant for the disease. <i>Arthritis and Rheumatism</i> , 2006, 54, 356-359.	6.7	25
98	Humoral autoimmunity against endothelium: theory or reality?. <i>Trends in Immunology</i> , 2005, 26, 275-281.	2.9	50
99	Prevalence of autoantibodies against structure specific recognition protein 1 in systemic lupus erythematosus. <i>Lupus</i> , 2004, 13, 463-468.	0.8	5
100	Haemostatic and inflammatory biomarkers in advanced chronic heart failure: role of oral anticoagulants and successful heart transplantation. <i>British Journal of Haematology</i> , 2004, 126, 85-92.	1.2	68
101	Innate immunity in the antiphospholipid syndrome: role of toll-like receptors in endothelial cell activation by antiphospholipid antibodies. <i>Autoimmunity Reviews</i> , 2004, 3, 510-515.	2.5	50
102	Imbalance of Osteoclastogenesis-Regulating Factors in Patients With Celiac Disease. <i>Journal of Bone and Mineral Research</i> , 2004, 19, 1112-1121.	3.1	91
103	Endothelial cell activation by antiphospholipid antibodies. <i>Clinical Immunology</i> , 2004, 112, 169-174.	1.4	91
104	Inflammatory response and the endothelium. <i>Thrombosis Research</i> , 2004, 114, 329-334.	0.8	68
105	Endothelium activation in the anti-phospholipid syndrome. <i>Biomedicine and Pharmacotherapy</i> , 2003, 57, 282-286.	2.5	18
106	Role of the MyD88 transduction signaling pathway in endothelial activation by antiphospholipid antibodies. <i>Blood</i> , 2003, 101, 3495-3500.	0.6	290
107	Prevalence and clinical significance of anti-cyclic citrullinated peptide antibodies in juvenile idiopathic arthritis. <i>Annals of the Rheumatic Diseases</i> , 2002, 61, 608-611.	0.5	65
108	Autoantibodies to fibroblasts induce a proadhesive and proinflammatory fibroblast phenotype in patients with systemic sclerosis. <i>Arthritis and Rheumatism</i> , 2002, 46, 1602-1613.	6.7	137

#	ARTICLE	IF	CITATIONS
109	Human monoclonal anti-endothelial cell IgG-derived from a systemic lupus erythematosus patient binds and activates human endothelium in vitro. <i>International Immunology</i> , 2001, 13, 349-357.	1.8	45
110	Interaction between chronically HIV-infected promonocytic cells and human umbilical vein endothelial cells: role of proinflammatory cytokines and chemokines in viral expression modulation. <i>Clinical and Experimental Immunology</i> , 2000, 120, 93-100.	1.1	22
111	Immunosuppressive activity of 15-deoxyspergualin on normal and autoimmune peripheral blood mononuclear cells. <i>European Journal of Pharmacology</i> , 1996, 311, 213-220.	1.7	5
112	Antiphospholipid and Antiendothelial Antibodies. <i>International Archives of Allergy and Immunology</i> , 1996, 111, 320-325.	0.9	2
113	In vitro type-1 and type-2 cytokine production in systemic lupus erythematosus: lack of relationship with clinical disease activity. <i>Lupus</i> , 1996, 5, 139-145.	0.8	63
114	In vitro production of type 1 and type 2 cytokines by peripheral blood mononuclear cells from high-risk HIV-negative intravenous drug users. <i>Aids</i> , 1995, 9, 691-694.	1.0	31
115	Protection from Experimental Autoimmune Thyroiditis in CBA Mice with the Novel Immunosuppressant Deoxyspergualin. <i>Scandinavian Journal of Immunology</i> , 1994, 39, 333-336.	1.3	10
116	̂ ² -Endorphin content in HIV-infected HuT78 cell line and in peripheral lymphocytes from HIV-positive subjects. <i>Peptides</i> , 1994, 15, 769-775.	1.2	14
117	TH1 and TH2 cytokine production by peripheral blood mononuclear cells from HIV-infected patients. <i>Aids</i> , 1994, 8, 757-762.	1.0	159
118	Antibodies to endothelial cells in primary vasculitides mediate in vitro endothelial cytotoxicity in the presence of normal peripheral blood mononuclear cells. <i>Clinical Immunology and Immunopathology</i> , 1992, 63, 267-274.	2.1	71
119	Enrichment of IgG anti-DNA-producing lymphoblastoid cell lines by antigen-coated immunomagnetic beads. <i>Clinical Immunology and Immunopathology</i> , 1992, 65, 39-44.	2.1	4
120	The Effects of Deoxyspergualin on the Development of Diabetes in Diabetes-Prone BB Rats. <i>Scandinavian Journal of Immunology</i> , 1992, 36, 415-420.	1.3	18
121	In vivo treatment with a monoclonal antibody to interferon-gamma neither affects the survival nor the incidence of lupus-nephritis in the MRL/lpr-lpr mouse. <i>Immunopharmacology</i> , 1992, 24, 11-16.	2.0	26
122	In vitro and ex vivo effect of tiaprofenic acid on human peripheral blood mononuclear cells. <i>International Journal of Immunopharmacology</i> , 1992, 14, 1279-1284.	1.1	1
123	Immunopharmacological activity of cefodizime in young and elderly subjects: In vitro and ex vivo studies. <i>Infection</i> , 1992, 20, S61-S63.	2.3	9
124	FK-506 prevents diabetes in diabetes-prone BB/Wor rats. <i>International Journal of Immunopharmacology</i> , 1991, 13, 1027-1030.	1.1	11
125	Immunopotentiating Activity of Thymopentin Treatment in Elderly Subjects. , 1990, , 537-550.		0
126	Heterogeneity of immune responsiveness in healthy elderly subjects. <i>Clinical Immunology and Immunopathology</i> , 1988, 47, 142-151.	2.1	57

#	ARTICLE	IF	CITATIONS
127	In vivo immunopotentiating activity of thymopentin in aging humans: Modulation of IL-2 receptor expression. <i>Clinical Immunology and Immunopathology</i> , 1988, 48, 140-149.	2.1	16
128	Experiences with Immunomodulant Agents in HIV Infections. <i>Acta Haematologica</i> , 1987, 78, 84-90.	0.7	4
129	In vivo immunopotentiating activity of thymopentin in aging humans: Increase of IL-2 production. <i>Clinical Immunology and Immunopathology</i> , 1987, 42, 151-159.	2.1	45
130	Anti-Phospholipid Antibodies and Coronavirus Disease 2019: Vaccination Does Not Trigger Early Autoantibody Production in Healthcare Workers. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	11